

Review Article

Potential Functions of the BMP Family in Bone, Obesity, and Glucose Metabolism

Yao Chen,¹ Bingwei Ma,² Xingchun Wang ,³ Xiaojuan Zha,³ Chunjun Sheng,³ Peng Yang,³ and Shen Qu ³

¹Chengdu Second People's Hospital, Chengdu 610017, China

²Department of Gastrointestinal Surgery, Shanghai Tenth People's Hospital Affiliated to Tongji University, Shanghai, China

³Thyroid Research Center of Shanghai, Shanghai 200072, China

Correspondence should be addressed to Shen Qu; qushencn@hotmail.com

Received 7 June 2020; Revised 15 February 2021; Accepted 8 June 2021; Published 24 June 2021

Academic Editor: Eric Hajdуч

Copyright © 2021 Yao Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Characteristic bone metabolism was observed in obesity and diabetes with controversial conclusions. Type 2 diabetes (T2DM) and obesity may manifest increased bone mineral density. Also, obesity is more easily to occur in T2DM. Therefore, we infer that some factors may be linked to bone and obesity as well as glucose metabolism, which regulate all of them. Bone morphogenetic proteins (BMPs), belonging to the transforming growth factor- (TGF-) beta superfamily, regulate a diverse array of cellular functions during development and in the adult. More and more studies revealed that there exists a relationship between bone metabolism and obesity as well as glucose metabolism. BMP2, BMP4, BMP6, BMP7, and BMP9 have been shown to affect the pathophysiological process of obesity and glucose metabolism beyond bone metabolism. They may exert functions in adipogenesis and differentiation as well as insulin resistance. In the review, we summarize the literature on these BMPs and their association with metabolic diseases including obesity and diabetes.

1. Introduction

The number of obesity and related metabolic disorders including type 2 diabetes (T2DM) is increasing worldwide with the changes in lifestyles [1]. Osteoporosis is also common, especially in women over 55 years old and men over 65 years old [2]. Osteoporosis is characterized by low BMD and microarchitectural deterioration of bone tissue leading to decreased bone strength and increased risk of fractures. The dual-energy X-ray absorptiometry (DXA) method is standard for determining BMD. However, DXA is a two-dimensional technique which cannot be used to measure true volumetric BMD and bone size or to separate trabecular from cortical bone. DXA cannot be used to measure bone microstructure or quality, which influences fracture risk [3]. Therefore, it is not capable of accurately assessing the fracture risk [4].

Bone mineral density (BMD) in obesity and T2DM is controversial, and the interaction between obesity, glucose metabolism, and bone metabolism is complexly linked to

many mechanical and biochemical factors [5]. More and more studies revealed that there exists a relationship between bone metabolism and obesity as well as glucose metabolism. Bone morphogenetic proteins (BMPs), a member of the transforming growth factor- (TGF-) β superfamily, which can be divided into 20 kinds of BMP are widely recognized. It has multifunctions that far exceed those of other members of the TGF family. BMP as a secreted protein is linked to many pathologies, including obesity and diabetes as well as related complications. The BMP family plays a role as a bridge between glucose metabolism and bone metabolism.

The central role of BMPs in the remodeling process of the human skeleton has been identified in numerous experimental and clinical studies [6]. BMPs have been shown to promote the osteogenic differentiation of murine multilineage cells (MMCs) and to promote bone formation in bone diseases [7]. BMPs appear to be key agents in the osteoblastic differentiation of mesenchymal stem cells, and more recent evidence implicates them to exert functions in the cells of

the osteoclastic lineage [6]. In vitro studies demonstrate that exogenous BMP activation increases osteoclastogenesis. BMP2, BMP4, BMP6, and BMP7 have been studied in the context of osteoporosis and have been associated with its pathophysiological pathways [6]. They complete these actions through both SMAD-dependent and SMAD-independent signaling pathways. BMP ligands interact with combinations of type 1 and type 2 receptors, which, in turn, activate effectors called receptor-activated- (RA-) SMADs. They translocate to the nucleus and accomplish gene regulation of genomic DNA.

In addition, BMPs are important regulators of adipogenesis and may play a role in obesity. Obesity is accompanied by an increase in both adipocyte number and size. The increase in adipocyte number is the result of recruitment to the adipocyte lineage of pluripotent stem cells present in the vascular stroma of adipose tissue. BMPs' signaling pathway has a dominant role in adipocyte lineage determination [8]. Also, they are related to obesity-related metabolic disorders including glucose metabolism [9] [10]. A research showed that BMP2 is correlated with diabetic status [10]. BMPs increase glucose uptake in mature 3T3-L1 adipocytes by PPAR γ and GLUT4 upregulation [11].

In this review, we summarize the BMPs which both affect bone and obesity as well as glucose metabolism to better understand the potential link between bone metabolism, obesity, and type 2 diabetes. These effects of BMPs (BMP9, BMP4, BMP2, BMP7, and BMP6) on bone, obesity, and glucose metabolism are shown in Figure 1.

2. Bone Metabolism in Obesity and Type 2 Diabetes

2.1. Bone Metabolism and Obesity. The interaction between obesity and bone metabolism is complexly related to many mechanical and biochemical factors [5]. The traditional view pointed out that obesity is protective against fractures. BMD in patients with obesity was significantly higher than that in the lean Chinese population [12]. However, another study finds that sarcopenic obesity is associated with the development of osteoporosis among the middle-aged and elderly Korean population [13]. Another study shows a negative relationship between waist circumference which represented abdominal obesity and BMD in the femoral neck and total hip [14]. In addition, the positive effects of body weight on BMD cannot counteract the detrimental effects of obesity on bone quality [15].

Besides, interventions of reducing body weight likely lead to bone loss over time. For example, the effects of bariatric surgery on BMD are dependent on the type of surgical procedure [5]. A meta-analysis regarding bone loss after bariatric surgery showed that BMD at the femoral neck decreased after bariatric surgery, compared to that in nonsurgical controls, while BMD at the lumbar spine did not show a difference between groups [16]. Change in bone occurring in obese men has been evaluated, with the results that found that femoral neck and total hip BMD decreased and spine BMD increased significantly after laparoscopic sleeve gastrectomy (LSG) [17].

2.2. Bone Metabolism and Diabetes. BMD in patients with T2DM is controversial. Individuals with diabetes have a higher or normal BMD compared with those without diabetes while with a higher fracture risk [18, 19]. The study finds that the risk of fragility fractures is increased in patients with either type 1 diabetes mellitus or T2DM [20]. The underlying mechanism may involve bone turnover which is decreased, and the bone material properties and microstructure of bone are altered in both diabetes [20]. Insulin deficiency in T1DM or loss of incretin effect in T2DM impaired the bone health as hyperglycemia impairs osteoblast function, generates abnormal modifications of the bone protein matrix, induces a state of chronic inflammation, and increases the risk of falls and fractures [21]. Also, associated factors create a milieu that promotes MSC fate toward adipogenesis over osteoblastogenesis which leads to a low bone turnover phenotype [21]. A large registry-based study showed that diabetes is associated with slightly greater BMD loss at the femoral neck but not at other parts of measurements including the lumbar spine or total hip when adjusted for both age and BMI [22].

Diabetic patients are at increased risk of fragility fractures, while the mechanism of bone fragility in these patients is likely multifactorial [23]. Data from the Osteoporotic Fractures in Men (MrOS) study were analyzed, with the results that showed that men with diabetes who are using insulin have an increased risk of nonvertebral fracture [24]. Another study showed that T2DM was not associated with higher prevalent or incident vertebral fractures in older men after adjustment for BMI and BMD [25]. Patients with T2DM have a higher fracture risk compared with nondiabetics, despite having higher BMD. However, greater insulin resistance is not found to be associated with increased fracture risk after adjustment for BMI and BMD, which is in contrast to the relationship between T2D and fracture risk [26].

BMD is measured by dual X-ray absorptiometry (DXA). However, BMD evaluation by DXA may be inadequate for evaluating the risk of fracture in the endocrine-related forms of osteoporosis such as obesity and diabetes [19]. Some new tools of noninvasively estimating bone quality have been done in the clinical practice for optimizing the fracture risk [27]. Overall, bone metabolism in obesity and diabetes needs to be further studied, and the factors affecting all of them need to be investigated and clarified.

3. BMPs and Bone

3.1. BMP9. BMP9 (also known as growth and differentiation factor- (GDF-) 2), as a member of the BMP family, which is secreted by nonhepatic parenchymal cells has a similarity of 50~55% with other BMPs including BMP2, BMP4, BMP5, BMP6, BMP7, and BMP8 [28]. And it plays multiple functions in humans including iron metabolism, chondrogenesis, neuronal differentiation, angiogenesis, glucose, and lipid metabolism except for inducing osteogenesis and chondrogenesis [9, 29–31].

Bone remodeling is tightly regulated through both bone resorption dominated by osteoclasts and bone formation dominated by osteoblasts with a dynamic process. Imbalance of bone remodeling may lead to pathological conditions, such




FIGURE 1: Effects of BMPs (BMP9, BMP4, BMP2, BMP7, and BMP6) on bone, obesity, and glucose metabolism. BMP: bone morphogenetic protein; WAT: white adipose tissue; BAT: brown adipose tissue; IR: insulin resistance; SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue; BMD: bone mineral density.

as osteoporosis. BMP9 predominantly produced in the liver has dual regulatory effects on bone remodeling. A study implemented in an ovariectomy mouse model found that BMP9 attenuates bone loss and improves bone biomechanical properties in vivo by increasing bone-forming activity and suppressing bone resorption activity [32]. BMP9 is an important factor in bone formation [7, 33, 34]. BMP9 significantly mediated callus formation and increased bone mass and strength in osteoporotic rats [33]. It increases the expression of mRNA levels of the osteoblast differentiation markers, such as ALP, Cola1, and OCN in MC3T3-E1 cells by upregulating LGR6 and activating the Wnt/ β -catenin pathway [32]. The expression of two key transcription factors (OSX and RUNX2) that regulate the target genes of osteoblastic differentiation was increased by BMP9 intervention [32].

Meanwhile, BMP9 suppresses receptor activator of nuclear factor- κ B (NF- κ B) ligand- (RANKL-) induced osteoclast differentiation of bone marrow macrophages (BMMs) by inhibiting the Akt-NF- κ B-NFATc1 pathway [32]. Therefore, BMP9 may be explored as an effective therapeutic strategy for osteoporosis [35–38].

3.2. BMP4. Bone loss in osteoporosis is caused by an imbalance between resorption and formation on endosteal surfaces of trabecular and cortical bone. BMP4 is identified as a bone-inducing factor with an important role in bone formation [39]. Injection of BMP4-transduced MSCs in mice induced bone formation [40]. Trabecular BMD determined by pQCT increased 20.5% at 14 days, and total BMD increased 6.5% at 14 days and 10.4% at 56 days in these animals [40]. BMP4 stimulates the synthesis of osteocalcin and osteoprotegerin via activation of the P38 MAPK signaling pathway in osteoblasts [41].

The BMP4 gene is associated with hip BMD in postmenopausal women, which is presumably via the regulation of anabolic effects on the skeleton [42]. The ex vivo gene therapy could be a promising tool for the treatment of osteoporotic fractures. Primary muscle-derived cells were isolated from the hindlimb muscle of rats and retrovirally transduced to express BMP4, with the results that found that the bone healing process in the osteoporotic bone was improved to the level similar to that of normal bone [43].

3.3. BMP2. BMP2 is used to augment bone formation, which is similar to other BMPs that are well known as osteogenic growth factors [44]. Recombinant human BMP2 significantly stimulated bone formation in diabetic animal and enhanced bone regeneration in normal animals which means that BMP2 may be beneficial in treating the deficient intramembranous bone formation in diabetes [45].

Sclerostin, an osteocyte product, is encoded by the SOST (sclerosteosis) gene on chromosome 17 in humans, inhibits bone formation, and therefore is an important regulator of bone mass [46, 47]. It binds to the LRP5/6 receptor and frizzled coreceptor on the osteoblast cell surface, thereby interfering with Wnt ligand binding and hence blocking osteoblast differentiation and activity [48]. It decreases osteoblast activity while maintaining osteoclast function which leads to a shift of the bone remodeling balance towards bone resorption and bone loss. Therefore, targeting sclerostin expression could be a valuable tool for the prevention of osteoporosis.

BMPs increase sclerostin levels [47]. Administered BMPs induce bone formation at osteoblastic levels and with the parallel induction of sclerostin expression preventing overstimulation of the anabolic processes or ectopic bone formation. The study found that high BMP2 doses stimulate sclerostin expression in a negative feedback loop to prevent bone

overgrowth and ectopic bone formation through the Wnt signaling pathway [48].

3.4. BMP7. BMP7 also known as osteogenic protein-1 (OP-1) is well established as having the osteoinductive activity. BMP7 mediated osteoblastic differentiation by recruiting stem cells to injured sites and induces osteoblast proliferation [49]. In addition, BMP7 inhibits osteoclast formation from monocyte precursor cells in vitro by interfering with signaling pathways [50]. Association of BMP7 and BMD was also investigated. BMP7 gene polymorphisms are associated with BMD in 920 European Americans. However, the common genetic polymorphisms of the BMP7 gene are not major contributors to variations in BMD or osteoporotic fracture in postmenopausal Chinese women.

Overall, better understanding of the mechanism of the BMP family on bone formation may help to prevent the development of osteoporosis.

4. BMPs and Obesity

4.1. BMP9

4.1.1. BMP9 in Humans with Obesity. In humans, a previous study has shown that plasma BMP9 concentrations were significantly associated with metabolic syndrome (Mets) even after controlling for anthropometric variables and lipid profiles, and its levels were significantly lower in 362 newly diagnosed patients with Mets compared to the healthy controls [9]. Obesity is an important component of the Mets. Plasma BMP9 levels were associated with the key components of Mets such as obesity, and its levels reduced progressively with an increasing number of Mets components [9]. And the best cutoff value for circulating BMP9 levels to predict Mets was 56.6 ng/L in humans [9]. Besides, plasma BMP9 was associated negatively with the waist-hip ratio (WHR) which represents abdominal obesity in these patients with Mets [9].

4.1.2. BMP9 and Adipose Tissue. In an animal experiment, the administration of BMP9 into obese mice expresses enhanced gene expression of fibroblast growth factor 21 (FGF21), which is a metabolic regulator, and reduced a spectrum of pathological symptoms caused by high-fat diet (HFD-) induced obesity [51]. Besides, BMP9 is effective to treat obesity-mediated nonalcoholic fatty liver disease (NAFLD) [51]. The animal study showed that BMP9 alleviated hepatic steatosis, serum levels of alanine aminotransferase (ALT), and total cholesterol [51]. BMP9-enhanced expression of FGF21 reduces a serum level of ALT as well as cholesterol. Fibroblast growth factor 21 (FGF21) is predominantly released from hepatocytes. FGF21 can induce fatty acid oxidation in WAT and suppress lipogenic genes in the liver to reduce triglyceride accumulation.

Brown adipose tissue (BAT), characterized by the expression of the thermogenic uncoupling protein 1 (UCP1), has recently been described in adult humans [52]. The effect of BAT on thermogenic activity is mainly controlled by the sympathetic nervous system [52]. Therefore, stimulation of BAT activity and/or recruitment of UCP1-positive cells are relevant targets for the treatment of obesity in humans [52].

A study has proven that BMP9 has a role in brown adipogenesis and suppressing pathophysiology of HFD-induced obesity in vitro [53]. BMP9 induced gene expression of uncoupling protein 1 (UCP1) and cell death-inducing DNA fragmentation factor-like effector A (CIDEA) but not in the visceral adipose tissues from the mice fed with HFD [53]. BMP9 leads to the activation of BAT thermogenesis, as well as to “browning” of white adipose tissue (WAT) [52].

Besides, systemic intraperitoneal injection of a recombinant BMP9 derivative suppressed weight gaining of high-fat diet-induced obese mice by reducing the sizes of white adipocytes [53]. The underlying mechanism of this effect may involve the activating receptor-like kinase 1 signaling pathway and enhance fatty acid synthase expression in the liver of obese mice [53].

Overall, BMP9 is closely associated with obesity, mainly reducing the bodyweight of decreasing WAT, enhancing the activity of BAT, and increasing BAT as well as “browning.” It may be a method for the treatment of obesity and obesity-related complications such as NAFLD as presented in Figure 2.

4.2. BMP4

4.2.1. BMP4 Levels in Patients with Obesity. A previous study also showed a relationship between BMP4 and obesity [54]. Serum BMP4 levels were significantly increased in subjects with obesity or Mets [55]. Kim et al. showed that serum BMP4 levels were decreased at 1 year after RYGB in 57 obese patients with diabetes [56]. Besides, serum BMP4 was proven to decrease at 3 and 6 months after LSG in females with obesity along with decreased BMD [57].

4.2.2. BMP4 and Adipose Tissue. BMP4 is secreted by adipose cells and increases in hypertrophic obesity which plays a key role in regulating adipogenic precursor cell commitment and differentiation [58]. BMP4, secreted by WAT, is an integral feedback regulator of both white and beige adipogenic commitment and differentiation [58]. Increased BMP4 in adipose cells preferentially regulates the beige/brown phenotype [58]. BMP4 plays a role in brown adipocyte formation and activity. It has a dual function in adipogenesis by inducing adipocyte commitment while inhibiting the acquisition of a brown phenotype during terminal differentiation [59]. This effect is mediated by Smad signaling and might be in part due to suppression of lipolysis, via regulation of hormone-sensitive lipase expression linked to reduced PPAR activity [59]. Also, in humans, there is a strong correlation between BMP4 levels and adipocyte size [59].

However, findings contrast with the above research that suggested that BMP4 has effects on white-to-brown transition in primary human adipose stem cells (hASCs) from subcutaneous AT [60]. BMP4 increased UCP1 expression in hASCs and decreased expression of the white-specific marker TCF21 [60]. Adding BMP4 during white adipogenic differentiation reactivated beige/brown markers [58]. BMP4 could also induce brown fat-like adipocytes in both white and brown preadipocytes, thereby decreasing the classical brown adipocyte marker *Zic1* and increasing the recently identified beige adipocyte marker *TMEM26* [61]. BMP4 promotes




FIGURE 2: BMP9 enhanced expression of FGF21 reduces a serum level of ALT as well as cholesterol and enhances brown adipogenesis, resulting in suppression of NAFLD and obesity.

brown adipocyte differentiation and thermogenesis *in vivo* and *in vitro* which offers a potentially new therapeutic approach for the treatment of obesity [61]. More studies are warranted to prove it.

4.3. BMP2. BMP2 may contribute to the partition of energy storage into visceral (VAT) and subcutaneous adipose tissue (SAT) [10]. BMP2 expression in both VAT and SAT was significantly higher in people with obesity when compared with individuals who were healthy and lean [10]. BMP2 mRNA was significantly higher in VAT compared with SAT in 547 individuals with a wide range of body mass index (BMI) [10]. Recent large-scale genome-wide association studies (GWAS) have identified a genetic variant rs979012 within BMP2 which was associated with the waist-to-hip ratio (WHR). That may be a mechanism of BMP2 in the regulation of fat distribution.

Besides, BMP2 is a potential plasma indicator of inflammatory status in middle-aged and elderly women [62]. The increased cardiovascular risk was positively correlated with BMP2 levels in overweight and obese middle-aged and elderly individuals [62].

4.4. BMP7

4.4.1. BMP7 and Adipose Tissue. BMP7 may be a promising tool for the treatment for obesity and associated comorbidities. Adipose tissue is central to the regulation of energy balance. WAT is the primary site of triglyceride storage while BAT and beige adipocytes are enriched in mitochondria with UCP1 to generate heat instead of ATP contributing to healthy energy balance. BMP7 is identified as an inducer of BAT differentiation [63, 64]. BMP7 can regulate brown adipogenesis and energy expenditure through a leptin-independent pathway [65] [64, 66]. BMP7 can regulate brown adipogenesis and energy expenditure through some factors, such as P38 MAPK, PRD M16, PGC-1, UCP-1, and mitochondrial biogenesis. Also, it affects browning [67] as presented in Figure 3. The autocrine mediator BMP7 led to moderate browning with the upregulation of the classical brown marker *Zic1* instead of *Tbx1* targets for enhancing thermogenesis in obesity [68]. Adenoviral-mediated expression of BMP7 in mice leads to a significant increase in




FIGURE 3: BMP7 can regulate brown adipogenesis and energy expenditure.

BAT, but not WAT, and results in an increase in energy expenditure and a reduction in weight gain [65].

4.4.2. BMP7 and Appetite. Energy intake and energy expenditure coordinate body weight. BMP7 exerts new function in appetite regulation [69]. Systemic treatment of diet-induced obese mice and *ob/ob* mice with BMP7 leads to a significantly decreased body weight by increasing energy expenditure and decreasing food intake and improved metabolism by a leptin-independent mechanism, at least partly by a central rapamycin-sensitive mTOR-p70S6 kinase pathway [69].

In a word, changes in a range of related factors are caused by metabolic disorders in the obesity including the BMP family. Studying the BMP family provides a better understanding of the pathophysiological mechanisms of obesity.

5. BMPs and Glucose Metabolism

5.1. BMP9. Plasma BMP9 is independently negatively correlated with insulin resistance (IR) assessed by homeostasis model assessment of insulin resistance (HOMA-IR) in Mets and newly diagnosed patients with T2DM [31] [9]. Furthermore, BMP9 mRNA and protein expressions were significantly decreased in muscle and adipose tissues of T2DM patients which suggests that BMP9 is likely to play an important role in insulin resistance [31].

In vitro, hepatic BMP9 expression was downregulated in IR mice and the overexpression of hepatic BMP9 improved IR in mice with HFD [30]. The level of insulin signaling molecule phosphorylation was increased in the livers of adenovirus-BMP9-treated mice and glucosamine-treated hepatocytes [30].

BMP9 whose expression is highest in the liver cell is likely to play an important role in glucose metabolism which is independently associated with T2DM [9, 31, 70]. In humans, hepatic BMP9 expression was downregulated in patients with diabetes [30]. Additionally, circulating BMP9 levels were

significantly higher in healthy subjects than in newly diagnosed patients with T2DM [31]. Besides, it negatively correlated with markers of glucose metabolism including HbA1c, fasting blood glucose (FBG), OGTT, and the area under the curve for glucose (AUC_{glucose}) [31]. Also, plasma BMP9 is associated negatively with FBG, 2-hour blood glucose after glucose overload (2 h-OGTT), and HbA1c in 362 newly diagnosed patients with Mets [9]. BMP9 is an important regulator of hepatic glucose metabolism [30]. The overexpression of hepatic BMP9 improved glucose tolerance in mice fed with HFD [30]. The expression of adenovirus-BMP9-treated mice and glucosamine-treated hepatocytes [30]. BMP9 enhances fatty acid synthase expression in the liver of obese mice, which may improve insulin resistance and help to attenuate blood glucose levels [53].

BMP9 can regulate glucose by inhibiting liver gluconeogenesis, transforming white adipose tissue to brown adipose tissue, promoting muscle glycogen synthesis, increasing the uptake and utilization of glucose by muscle tissue, increasing liver and adipose tissue insulin sensitivity, and promoting insulin synthesis and secretion [71]. It has been confirmed that BMP9, like insulin, improves glycemia in diabetic mice and regulates directional glucose metabolism in hepatocytes. Therefore, the hypoglycemic potential of BMP9 is of great interest. It is proposed to be a candidate hepatic insulin-sensitizing substance (HISS) [72, 73].

5.2. BMP4. Moreover, increasing studies have demonstrated the effects of BMP4 in both bone and glucose metabolism [58, 59, 74, 75]. Hyperglycemia and free fatty acid stimulate BMP4 expression [76]. BMP4 is upregulated in diabetic animals with inhibition of glucose-stimulated insulin secretion in rodent pancreatic islets in a calbindin 1-dependent manner [77]. A study from Christensen et al. shows that prolonged exposure to BMP4 reduced glucose-stimulated insulin secretion in rodent pancreatic islets. BMP4 can significantly induce the expression of the Ca (2+)-binding protein calbindin 1 and reduce Ca (2+) current through voltage-dependent Ca (2+) channels. The decrease in Ca (2+) channel activity leads to diminished insulin exocytosis.

BMP4 plays a role in the regulation of glucose homeostasis by inhibiting insulin signaling via activation of PKC- θ isoform, which results in insulin resistance [78]. BMP4 levels are significantly associated with insulin sensitivity in humans [59].

5.3. BMP2. BMP2 serum concentrations were significantly higher in patients with T2DM [10]. The BMP2 pathway may be a promising new drug target to treat IR with insulin-sensitizing effect by enhancing insulin-mediated glucose uptake in both insulin-sensitive and insulin-insensitive adipocytes [11]. BMP2 has a direct effect on the translocation of the GLUT4 to the plasma membrane and demonstrates that these BMP2 increase GLUT4 protein levels equipotent to rosiglitazone [11]. Also, BMP2 is a potential therapeutic target to prevent or treat diabetic retinopathy. A recent in vitro study found that BMP2 impacts Vascular Endothelial Growth Factor (VEGF) expression in cultured Müller cells. VEGF has always been regarded as a key player in the path-

ogenesis and progression of DR due to its potent proangiogenic and proinflammatory effects. This finding suggests that the effect was not linked to glycemic balance [79].

5.4. BMP7. BMP7 provides new insights into treating insulin resistance-related disorders such as T2DM. BMP7 regulates hepatic insulin sensitivity. Ma et al. found that hepatic BMP7 expression is reduced in HFD-induced diabetic mice and palmitate-induced insulin-resistant HepG2 and AML12 cells [80]. BMP7 improves the insulin signaling pathway in IR hepatocytes while knockdown of BMP7 further impairs insulin signal transduction in PA-treated cells [80]. Both in vitro and in vivo, the study showed that hepatic BMP7 has a novel function in regulating insulin sensitivity through inhibition of mitogen-activated protein kinases (MAPKs) in both the liver of obese mice and PA-treated cells [80]. BMP7 is an attractive candidate for tackling diabetes. It causes improved glucose uptake and ameliorates peripheral IR by potentiating insulin signaling of the PI3K/AKT pathway in mice with T2DM [78]. BMP7 may stimulate insulin secretion and improve islet cell function in nondiabetic individuals, with the results showing that serum BMP7 concentrations were positively correlated with HOMA-B (insulin secretion index) and fasting insulin [81].

5.5. BMP6. BMP6 is efficient in bone formation [82–84]. BMP6 improves glycemia in T2D mice and regulates glucose metabolism in hepatocytes. Treatment of ob/ob mice with BMP6 for 6 days resulted in reduced circulating glucose and lipid levels [85]. BMP6 improved the glucose excursion during an OGTT, lowering the total glycemic response by 21% [85]. BMP6 inhibited gluconeogenesis and glucose output via downregulating the PepCK expression in rat H4IIE hepatoma cells [85]. Moreover, BMP6 inhibited glucose production regardless of the presence of cAMP [85]. Besides, the BMP6 pathway is a promising new drug target to treat IR [11]. BMP6 leads to enhanced insulin-mediated glucose uptake in both insulin-sensitive and insulin-insensitive adipocytes [11]. BMP6 has a direct effect on the translocation of GLUT4 to the plasma membrane and demonstrates that these BMP6 increase GLUT4 protein levels equal to rosiglitazone [11]. In addition, BMP6 may provide a means to enhance the amount of myogenic lineage-derived BAT, which plays a pivotal role in promoting energy expenditure [84, 86]. BMP6 might serve as a novel therapeutic for obesity by enhancing the amount of myogenic lineage-derived BAT [84, 86]. Therefore, the BMP family may be an exciting prospect for future treatments of diabetes as BMP2, BMP6, BMP7, and BMP 9 have function of improving glucose metabolism.

6. Conclusion

Overall, BMPs, mainly including BMP9, BMP4, BMP2, and BMP7, may exert functions both in bone and in obesity as well as glucose metabolism. A full understanding of the effects of BMPs may help to better understand the bone metabolism in obesity as well as type 2 diabetes. The BMPs may play a role as a bridge among bone, obesity, and glucose metabolism.

Abbreviations

T2DM:	Type 2 diabetes
BMD:	Bone mineral density
BMPs:	Bone morphogenetic proteins
TGF:	Transforming growth factor
MMCs:	Murine multilineage cells
GDF-2:	Differentiation factor
NF- κ B:	Nuclear factor- κ B
Mets:	Metabolic syndrome
WHR:	Waist-hip ratio
FGF21:	Fibroblast growth factor 21
HFD:	High-fat diet
NAFLD:	Nonalcoholic fatty liver disease
ALT:	Aminotransferase
BAT:	Brown adipose tissue
UCP1:	Uncoupling protein 1
WAT:	White adipose tissue.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors' Contributions

XC W and BW M performed and drafted the manuscript. XJ Z and CJ S were involved in preparing the references. PY helped to review the manuscript. YC helped to revise the manuscript. S Q designed the study and approved the final version. All authors read and approved the final manuscript. Yao Chen, Bingwei Ma, and Xingchun Wang are co-first authors.

Acknowledgments

This research was supported by the National Natural Science Foundation of China (NSFC 81970677).

References

- [1] P. Gonzalez-Muniesa, M. A. Martinez-Gonzalez, F. B. Hu et al., "Obesity," *Nature Reviews Disease Primers*, vol. 3, p. 17034, 2017.
- [2] J. E. Compston, M. R. McClung, and W. D. Leslie, "Osteoporosis," *The Lancet*, vol. 393, no. 10169, pp. 364–376, 2019.
- [3] S. L. Bonnick, "Current controversies in bone densitometry," *Current Opinion in Rheumatology*, vol. 14, no. 4, pp. 416–420, 2002.
- [4] M. Lorentzon and S. R. Cummings, "Osteoporosis: the evolution of a diagnosis," *Journal of Internal Medicine*, vol. 277, no. 6, pp. 650–661, 2015.
- [5] C. Savvidis, S. Tournis, and A. D. Dede, "Obesity and bone metabolism," *Hormones*, vol. 17, no. 2, pp. 205–217, 2018.
- [6] N. K. Kanakaris, G. Petsatodis, M. Tagil, and P. V. Giannoudis, "Is there a role for bone morphogenetic proteins in osteoporotic fractures?," *Injury*, vol. 40, Supplement 3, pp. S21–S26, 2009.
- [7] Q. Song, L. Zhong, C. Chen et al., "miR-21 synergizes with BMP9 in osteogenic differentiation by activating the BMP9/Smad signaling pathway in murine multilineage cells," *International Journal of Molecular Medicine*, vol. 36, no. 6, pp. 1497–1506, 2015.
- [8] H. Huang, T. J. Song, X. Li et al., "BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage," *Proceedings of the National Academy of Sciences*, vol. 106, no. 31, pp. 12670–12675, 2009.
- [9] X. Xu, X. Li, G. Yang et al., "Circulating bone morphogenetic protein-9 in relation to metabolic syndrome and insulin resistance," *Scientific Reports*, vol. 7, no. 1, p. 17529, 2017.
- [10] E. Guiu-Jurado, M. Unthan, N. Bohler et al., "Bone morphogenetic protein 2 (BMP2) may contribute to partition of energy storage into visceral and subcutaneous fat depots," *Obesity*, vol. 24, no. 10, pp. 2092–2100, 2016.
- [11] I. Schreiber, G. Dorpholz, C. E. Ott et al., "BMPs as new insulin sensitizers: enhanced glucose uptake in mature 3T3-L1 adipocytes via PPAR γ and GLUT4 upregulation," *Scientific Reports*, vol. 7, no. 1, p. 17192, 2017.
- [12] C. H. Kao, C. C. Chen, and S. J. Wang, "Normal data for lumbar spine bone mineral content in healthy elderly Chinese: influences of sex, age, obesity and ethnicity," *Nuclear Medicine Communications*, vol. 15, no. 11, pp. 916–920, 1994.
- [13] J. H. Chung, H. J. Hwang, H. Y. Shin, and C. H. Han, "Association between sarcopenic obesity and bone mineral density in middle-aged and elderly Korean," *Annals of Nutrition and Metabolism*, vol. 68, no. 2, pp. 77–84, 2016.
- [14] W. Chung, J. Lee, and O. H. Ryu, "Is the negative relationship between obesity and bone mineral content greater for older women?," *Journal of Bone and Mineral Metabolism*, vol. 32, no. 5, pp. 505–513, 2014.
- [15] S. A. Shapses, L. C. Pop, and Y. Wang, "Obesity is a concern for bone health with aging," *Nutrition Research*, vol. 39, pp. 1–13, 2017.
- [16] B. J. Ko, S. K. Myung, K. H. Cho et al., "Relationship between bariatric surgery and bone mineral density: a meta-analysis," *Obesity Surgery*, vol. 26, no. 7, pp. 1414–1421, 2016.
- [17] P. Adamczyk, M. Buzga, P. Holeczy et al., "Bone mineral density and body composition after laparoscopic sleeve gastrectomy in men: a short-term longitudinal study," *International Journal of Surgery*, vol. 23, pp. 101–107, 2015.
- [18] K. L. Holloway-Kew, N. Marijanovic, L. L. F. De Abreu, M. A. Sajjad, J. A. Pasco, and M. A. Kotowicz, "Bone mineral density in diabetes and impaired fasting glucose," *Osteoporosis International*, vol. 30, pp. 1799–1806, 2019.
- [19] C. Eller-Vainicher, E. Cairoli, G. Grassi et al., "Pathophysiology and management of type 2 diabetes mellitus bone fragility," *Journal of Diabetes Research*, vol. 2020, Article ID 7608964, 18 pages, 2020.
- [20] N. Napoli, M. Chandran, D. D. Pierroz, B. Abrahamsen, A. V. Schwartz, and S. L. Ferrari, "Mechanisms of diabetes mellitus-induced bone fragility," *Nature Reviews Endocrinology*, vol. 13, no. 4, pp. 208–219, 2017.
- [21] N. Napoli, R. Strollo, A. Paladini, S. I. Briganti, P. Pozzilli, and S. Epstein, "The alliance of mesenchymal stem cells, bone, and diabetes," *International Journal of Endocrinology*, vol. 2014, Article ID 690783, 26 pages, 2014.
- [22] W. D. Leslie, S. N. Morin, S. R. Majumdar, and L. M. Lix, "Effects of obesity and diabetes on rate of bone density loss," *Osteoporosis International*, vol. 29, no. 1, pp. 61–67, 2018.
- [23] S. L. Ferrari, B. Abrahamsen, N. Napoli et al., "Diagnosis and management of bone fragility in diabetes: an emerging

- challenge,” *Osteoporosis International*, vol. 29, no. 12, pp. 2585–2596, 2018.
- [24] N. Napoli, E. S. Strotmeyer, K. E. Ensrud et al., “Fracture risk in diabetic elderly men: the MrOS study,” *Diabetologia*, vol. 57, no. 10, pp. 2057–2065, 2014.
- [25] N. Napoli, A. V. Schwartz, A. L. Schafer et al., “Vertebral fracture risk in diabetic elderly men: the MrOS study,” *Journal of Bone and Mineral Research*, vol. 33, no. 1, pp. 63–69, 2018.
- [26] N. Napoli, C. Conte, C. Pedone et al., “Effect of insulin resistance on BMD and fracture risk in older adults,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 104, no. 8, pp. 3303–3310, 2019.
- [27] C. Eller-Vainicher, A. Falchetti, L. Gennari et al., “Diagnosis of endocrine disease: evaluation of bone fragility in endocrine disorders,” *European Journal of Endocrinology*, vol. 180, no. 6, pp. R213–R232, 2019.
- [28] M. Bidart, N. Ricard, S. Levet et al., “BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain,” *Cellular and Molecular Life Sciences*, vol. 69, no. 2, pp. 313–324, 2012.
- [29] J. Bi and S. Ge, “Potential roles of BMP9 in liver fibrosis,” *International Journal of Molecular Sciences*, vol. 15, no. 11, pp. 20656–20667, 2014.
- [30] M. Yang, Z. Liang, M. Yang et al., “Role of bone morphogenetic protein-9 in the regulation of glucose and lipid metabolism,” *The FASEB Journal*, vol. 33, no. 9, pp. 10077–10088, 2019.
- [31] Y. Luo, L. Li, X. Xu et al., “Decreased circulating BMP-9 levels in patients with type 2 diabetes is a signature of insulin resistance,” *Clinical Science*, vol. 131, no. 3, pp. 239–246, 2017.
- [32] Y. M. Zhou, Y. Y. Yang, Y. X. Jing et al., “BMP9 reduces bone loss in ovariectomized mice by dual regulation of bone remodeling,” *Journal of Bone and Mineral Research*, vol. 35, no. 5, pp. 978–993, 2020.
- [33] X. Wang, J. Huang, F. Huang et al., “Bone morphogenetic protein 9 stimulates callus formation in osteoporotic rats during fracture healing,” *Molecular Medicine Reports*, vol. 15, no. 5, pp. 2537–2545, 2017.
- [34] X. Y. Su, X. Zou, Q. Z. Chen et al., “Follicle-stimulating hormone beta-subunit potentiates bone morphogenetic protein 9-induced osteogenic differentiation in mouse embryonic fibroblasts,” *Journal of Cellular Biochemistry*, vol. 118, pp. 1792–1802, 2017.
- [35] Y. Liu, Y. Liu, R. Zhang et al., “All-trans retinoic acid modulates bone morphogenetic protein 9-induced osteogenesis and adipogenesis of preadipocytes through BMP/Smad and Wnt/beta-catenin signaling pathways,” *The International Journal of Biochemistry & Cell Biology*, vol. 47, pp. 47–56, 2014.
- [36] I. Vhora, R. Lalani, P. Bhatt, S. Patil, and A. Misra, “Lipid-nucleic acid nanoparticles of novel ionizable lipids for systemic BMP-9 gene delivery to bone-marrow mesenchymal stem cells for osteoinduction,” *International Journal of Pharmaceutics*, vol. 563, pp. 324–336, 2019.
- [37] X. Chen, S. Zhang, X. Chen et al., “Emodin promotes the osteogenesis of MC3T3-E1 cells via BMP-9/Smad pathway and exerts a preventive effect in ovariectomized rats,” *Acta Biochimica et Biophysica Sinica*, vol. 49, no. 10, pp. 867–878, 2017.
- [38] I. Vhora, R. Lalani, P. Bhatt et al., “Colloidally stable small unilamellar stearyl amine lipoplexes for effective BMP-9 gene delivery to stem cells for osteogenic differentiation,” *AAPS PharmSciTech*, vol. 19, no. 8, pp. 3550–3560, 2018.
- [39] J. Massague and Y. G. Chen, “Controlling TGF-beta signaling,” *Genes & Development*, vol. 14, pp. 627–644, 2000.
- [40] X. S. Zhang, T. A. Linkhart, S. T. Chen et al., “Local ex vivo gene therapy with bone marrow stromal cells expressing human BMP4 promotes endosteal bone formation in mice,” *The Journal of Gene Medicine*, vol. 6, no. 1, pp. 4–15, 2004.
- [41] G. Kuroyanagi, H. Tokuda, N. Yamamoto et al., “Resveratrol amplifies BMP-4-stimulated osteoprotegerin synthesis via p38 MAP kinase in osteoblasts,” *Molecular Medicine Reports*, vol. 12, no. 3, pp. 3849–3854, 2015.
- [42] L. Ramesh Babu, S. G. Wilson, I. M. Dick, F. M. A. Islam, A. Devine, and R. L. Prince, “Bone mass effects of a BMP4 gene polymorphism in postmenopausal women,” *Bone*, vol. 36, pp. 555–561, 2005.
- [43] T. Rose, H. Peng, A. Usas, C. Josten, F. H. Fu, and J. Huard, “Ex-vivo gene therapy with BMP-4 for critically sized defects and enhancement of fracture healing in an osteoporotic animal model,” *Der Unfallchirurg*, vol. 108, pp. 25–34, 2005.
- [44] K. Ishida and D. R. Haudenschild, “Interactions between FGF21 and BMP-2 in osteogenesis,” *Biochemical and Biophysical Research Communications*, vol. 432, no. 4, pp. 677–682, 2013.
- [45] R. B. de Santana and P. C. Trackman, “Effect of targeted delivery of bone morphogenetic protein-2 on bone formation in type 1 diabetes,” *The International Journal of Oral & Maxillofacial Implants*, vol. 30, no. 3, pp. 707–714, 2015.
- [46] Y. H. Ma, A. V. Schwartz, S. Sigurdsson et al., “Circulating sclerostin associated with vertebral bone marrow fat in older men but not women,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 99, no. 12, pp. E2584–E2590, 2014.
- [47] B. Siegenthaler, C. Ghayor, B. Gjoksi-Cosandey, N. Ruangsawasdi, and F. Weber, “The bromodomain inhibitor N-methyl pyrrolidone prevents osteoporosis and BMP-triggered sclerostin expression in osteocytes,” *International Journal of Molecular Sciences*, vol. 19, no. 11, p. 3332, 2018.
- [48] R. Y. Kim, H. J. Yang, Y. M. Song, I. S. Kim, and S. J. Hwang, “Estrogen modulates bone morphogenetic protein-induced sclerostin expression through the Wnt signaling pathway,” *Tissue Engineering Part A*, vol. 21, no. 13–14, pp. 2076–2088, 2015.
- [49] K. Lavery, S. Hawley, P. Swain, R. Rooney, D. Falb, and M. H. Alaoui-Ismaïli, “New insights into BMP-7 mediated osteoblastic differentiation of primary human mesenchymal stem cells,” *Bone*, vol. 45, no. 1, pp. 27–41, 2009.
- [50] T. Maurer, G. Zimmermann, S. Maurer, S. Stegmaier, C. Wagner, and G. M. Hänsch, “Inhibition of osteoclast generation: a novel function of the bone morphogenetic protein 7/osteogenic protein 1,” *Mediators of Inflammation*, vol. 2012, Article ID 171209, 9 pages, 2012.
- [51] S. Kim, S. Choe, and D. K. Lee, “BMP-9 enhances fibroblast growth factor 21 expression and suppresses obesity,” *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1862, no. 7, pp. 1237–1246, 2016.
- [52] A. L. Poher, J. Altirriba, C. Veyrat-Durebex, and F. Å. Rohrer-Jeanrenaud, “Brown adipose tissue activity as a target for the treatment of obesity/insulin resistance,” *Frontiers in Physiology*, vol. 6, 2015.
- [53] M. M. Kuo, S. Kim, C. Y. Tseng, Y.-H. Jeon, S. Choe, and D. K. Lee, “BMP-9 as a potent brown adipogenic inducer with anti-obesity capacity,” *Biomaterials*, vol. 35, no. 10, pp. 3172–3179, 2014.

- [54] Y. Macotela, B. Emanuelli, M. A. Mori et al., "Intrinsic differences in adipocyte precursor cells from different white fat depots," *Diabetes*, vol. 61, pp. 1691–1699, 2012.
- [55] J. W. Son, M. K. Kim, Y. M. Park et al., "Association of serum bone morphogenetic protein 4 levels with obesity and metabolic syndrome in non-diabetic individuals," *Endocrine Journal*, vol. 58, pp. 39–46, 2011.
- [56] M. K. Kim, E. H. Jang, O. K. Hong et al., "Changes in serum levels of bone morphogenic protein 4 and inflammatory cytokines after bariatric surgery in severely obese Korean patients with type 2 diabetes," *International Journal of Endocrinology*, vol. 2013, Article ID 681205, 2013.
- [57] X. Wang, L. Li, C. Zhu, J. Gao, and S. Qu, "Alteration of bone mineral density differs between genders in obese subjects after laparoscopic sleeve gastrectomy: bone morphogenetic protein 4 may count," *Obesity Surgery*, vol. 28, no. 10, pp. 3221–3226, 2018.
- [58] B. Gustafson, A. Hammarstedt, S. Hedjazifar et al., "BMP4 and BMP antagonists regulate human white and beige adipogenesis," *Diabetes*, vol. 64, no. 5, pp. 1670–1681, 2015.
- [59] S. Modica, L. G. Straub, M. Balaz et al., "Bmp4 promotes a brown to white-like adipocyte shift," *Cell Reports*, vol. 16, no. 8, pp. 2243–2258, 2016.
- [60] M. Elsen, S. Raschke, N. Tennagels et al., "BMP4 and BMP7 induce the white-to-brown transition of primary human adipose stem cells," *American Journal of Physiology-Cell Physiology*, vol. 306, pp. C431–C440, 2014.
- [61] R. Xue, Y. Wan, S. Zhang, Q. Zhang, H. Ye, and Y. Li, "Role of bone morphogenetic protein 4 in the differentiation of brown fat-like adipocytes," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 306, no. 4, pp. E363–E372, 2014.
- [62] S. Ribeiro, L. R. Lopes, G. Paula Costa et al., "CXCL-16, IL-17, and bone morphogenetic protein 2 (BMP-2) are associated with overweight and obesity conditions in middle-aged and elderly women," *Immunity & Ageing*, vol. 14, no. 1, 2017.
- [63] M. R. Boon, S. A. van den Berg, Y. Wang et al., "BMP7 activates brown adipose tissue and reduces diet-induced obesity only at subthermoneutrality," *PLoS One*, vol. 8, no. 9, p. e74083, 2013.
- [64] S. Saini, A. J. Duraisamy, S. Bayen, P. Vats, and S. B. Singh, "Role of BMP7 in appetite regulation, adipogenesis, and energy expenditure," *Endocrine*, vol. 48, pp. 405–409, 2015.
- [65] Y. H. Tseng, E. Kokkotou, T. J. Schulz et al., "New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure," *Nature*, vol. 454, no. 7207, pp. 1000–1004, 2008.
- [66] C. Contreras, F. Gonzalez, J. Ferno et al., "The brain and brown fat," *Annals of Medicine*, vol. 47, no. 2, pp. 150–168, 2015.
- [67] M. Elsen, S. Raschke, and J. Eckel, "Browning of white fat: does irisin play a role in humans?," *Journal of Endocrinology*, vol. 222, no. 1, pp. R25–R38, 2014.
- [68] A. Klusoczki, Z. Vereb, A. Vamos et al., "Differentiating SGBS adipocytes respond to PPARgamma stimulation, irisin and BMP7 by functional browning and beige characteristics," *Scientific Reports*, vol. 9, no. 1, p. 5823, 2019.
- [69] K. L. Townsend, R. Suzuki, T. L. Huang et al., "Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway," *The FASEB Journal*, vol. 26, no. 5, pp. 2187–2196, 2012.
- [70] Y. Jia, D. Niu, Q. Li et al., "Effective gene delivery of shBMP-9 using polyethyleneimine-based core-shell nanoparticles in an animal model of insulin resistance," *Nanoscale*, vol. 11, no. 4, pp. 2008–2016, 2019.
- [71] Y. Wang, C. Ma, T. Sun, and L. Ren, "Potential roles of bone morphogenetic protein-9 in glucose and lipid homeostasis," *Journal of Physiology and Biochemistry*, vol. 76, no. 4, pp. 503–512, 2020.
- [72] I. Sosa, O. Cvijanovic, T. Celic et al., "Hepatoregenerative role of bone morphogenetic protein-9," *Medical Science Monitor*, vol. 17, pp. HY33–HY35, 2011.
- [73] I. Sosa and A. Grubestic, "Putative hormone with anti-obesogenic and insulin-sensitizing effect," *International Journal of Immunopathology and Pharmacology*, vol. 29, no. 1, pp. 147–148, 2016.
- [74] B. Gustafson, A. Hammarstedt, S. Hedjazifar, and U. Smith, "Restricted adipogenesis in hypertrophic obesity: the role of WISP2, WNT, and BMP4," *Diabetes*, vol. 62, no. 9, pp. 2997–3004, 2013.
- [75] R. R. Bowers, J. W. Kim, T. C. Otto, and M. D. Lane, "Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene," *Proceedings of the National Academy of Sciences*, vol. 103, no. 35, pp. 13022–13027, 2006.
- [76] O.-K. Hong, S.-J. Yoo, J.-W. Son et al., "High glucose and palmitate increases bone morphogenic protein 4 expression in human endothelial cells," *The Korean Journal of Physiology & Pharmacology*, vol. 20, no. 2, pp. 169–175, 2016.
- [77] G. L. Christensen, M. L. Jacobsen, A. Wendt et al., "Bone morphogenetic protein 4 inhibits insulin secretion from rodent beta cells through regulation of calbindin1 expression and reduced voltage-dependent calcium currents," *Diabetologia*, vol. 58, pp. 1282–1290, 2015.
- [78] T. Chattopadhyay, R. R. Singh, S. Gupta, and A. Surolia, "Bone morphogenetic protein-7 (BMP-7) augments insulin sensitivity in mice with type II diabetes mellitus by potentiating PI3K/AKT pathway," *Biofactors*, vol. 43, pp. 195–209, 2017.
- [79] K. A. Hussein, K. Choksi, S. Akeel et al., "Bone morphogenetic protein 2: a potential new player in the pathogenesis of diabetic retinopathy," *Experimental Eye Research*, vol. 125, pp. 79–88, 2014.
- [80] H. Ma, J. Yuan, J. Ma et al., "BMP7 improves insulin signal transduction in the liver via inhibition of mitogen-activated protein kinases," *Journal of Endocrinology*, vol. 243, pp. 97–110, 2019.
- [81] J. Zeng, Y. Jiang, S. Xiang, and B. Chen, "Serum bone morphogenetic protein 7, insulin resistance, and insulin secretion in non-diabetic individuals," *Diabetes Research and Clinical Practice*, vol. 93, no. 1, pp. e21–e24, 2011.
- [82] O. Mizrahi, D. Sheyn, W. Tawackoli et al., "BMP-6 is more efficient in bone formation than BMP-2 when overexpressed in mesenchymal stem cells," *Gene Therapy*, vol. 20, no. 4, pp. 370–377, 2013.
- [83] C. J. Li, V. Madhu, G. Balian, A. S. Dighe, and Q. Cui, "Cross-talk between VEGF and BMP-6 pathways accelerates osteogenic differentiation of human adipose-derived stem cells," *Journal of Cellular Physiology*, vol. 230, no. 11, pp. 2671–2682, 2015.
- [84] B. O. Diekman, B. T. Estes, and F. Guilak, "The effects of BMP6 overexpression on adipose stem cell chondrogenesis: interactions with dexamethasone and exogenous growth factors," *Journal of Biomedical Materials Research Part A*, vol. 93, pp. 994–1003, 2010.

- [85] M. Pauk, T. Bordukalo-Niksic, J. Brkljacic et al., "A novel role of bone morphogenetic protein 6 (BMP6) in glucose homeostasis," *Acta Diabetologica*, vol. 56, no. 3, pp. 365–371, 2019.
- [86] A. Sharma, C. Huard, C. Vernochet et al., "Brown fat determination and development from muscle precursor cells by novel action of bone morphogenetic protein 6," *PLoS One*, vol. 9, no. 3, p. e92608, 2014.